BioCentury
ARTICLE | Company News

Alvine grants AbbVie option for celiac compound

May 15, 2013 12:39 AM UTC

Alvine Pharmaceuticals Inc. (San Carlos, Calif.) granted AbbVie Inc. (NYSE:ABBV) an exclusive option to acquire the company or its ALV003, which is in Phase II testing to treat celiac disease, under u...